Want to see EVFM full AI Analyst Report?
EVFM Stock Chart & Stats
$0.01
>-$0.01(-8.76%)
At close: 4:00 PM EST
$0.01
>-$0.01(-8.76%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume1.62M
Average Volume (3M)589.38K
Market Cap
$1.06M
Enterprise Value$51.24M
Total Cash (Recent Filing)$2.38M
Total Debt (Recent Filing)$52.46M
Price to Earnings (P/E)―
Beta-0.15
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding132,530,080
10 Day Avg. Volume412,838
30 Day Avg. Volume589,380
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap48.51
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit3.42
Enterprise Value/Ebitda-17.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~75% gross margin from the product mix (Phexxi, Solosec) provides a durable profitability lever: as sales scale, high gross margins can convert incremental revenue into operating income, helping absorb fixed costs and support reinvestment in commercialization and R&D over months.
Commercial Expansion Via Solosec Africa DealThe exclusive five-year distribution pact opens a large, underpenetrated epidemiological market and uses Evofem's existing FDA dossier to accelerate regulatory access. A dedicated local partner reduces go-to-market costs and can provide steady, multi-year revenue if adoption follows public-health need.
Cost Reductions And Path To Operating ProfitManagement's significant expense cuts and manufacturing cost initiatives produced the company's first operating profit, indicating improved cost structure and operational discipline. Combined with clinical study support for Solosec, these moves strengthen the prospect of sustained profitability if trends continue.
Bears Say
Highly Leveraged, Negative EquityDeeply negative equity and sizable debt create a thin capitalization profile that materially raises insolvency and refinancing risk. This restricts financing options, invites creditor controls or covenants, and increases the likelihood of dilutive or expensive financing, undermining long-term flexibility.
Weak Cash GenerationPersistent negative operating and free cash flow means the business remains dependent on external capital to fund operations and expansion. The sharp deterioration in FCF growth reduces the buffer for regulatory, commercial, or manufacturing investments and elevates near-term liquidity vulnerability.
Volatile Profitability Reliant On One-offsEarnings have swung materially year-to-year with the latest operating profit partly driven by nonrecurring items. Reliance on one-offs reduces predictability of future earnings, complicates budgeting and partner confidence, and risks a return to losses absent sustainable revenue or cost improvements.
Evofem Biosciences News
EVFM FAQ
What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Evofem Biosciences’s market cap?
Evofem Biosciences’s market cap is $1.06M.
When is Evofem Biosciences’s upcoming earnings report date?
Evofem Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 48 days.
How were Evofem Biosciences’s earnings last quarter?
Evofem Biosciences released its earnings results on May 18, 2026. The company reported -$0.041 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.041.
Is Evofem Biosciences overvalued?
According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued.
Does Evofem Biosciences pay dividends?
Evofem Biosciences does not currently pay dividends.
What is Evofem Biosciences’s EPS estimate?
Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evofem Biosciences have?
Evofem Biosciences has 132,530,080 shares outstanding.
What happened to Evofem Biosciences’s price movement after its last earnings report?
Evofem Biosciences reported an EPS of -$0.041 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evofem Biosciences?
Currently, no hedge funds are holding shares in EVFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evofem Biosciences
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---